Extract

The objective of this trial is to study the activity and the safety of the 1st line treatment with Ibrutinib in combination with Rituximab for patients with advanced follicular lymphoma in need of therapy.

Inclusion criteria

• Follicular Lymphoma (FL), advanced disease in need of therapy